Casirivimab and Imdevimab recall in Canada: high risk of treatment failure
In plain language
This recall involves Casirivimab and Imdevimab concentrate for infusion sold in Canada. It's being recalled because it may have a high risk of treatment failure against the SARS-CoV-2 Omicron variant. Healthcare professionals should consider other therapies if the Omicron variant cannot be ruled out.
What to do
- Stop using the product if the Omicron variant cannot be ruled out.
- Consult with a healthcare professional for alternative treatments.
- Report any side effects to Hoffmann-La Roche Limited or Health Canada.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
Casirivimab and Imdevimab concentrate for infusion (6 mL vial size)
Model: DIN 02516691
Casirivimab and Imdevimab concentrate for infusion (20 mL vial size)
Model: DIN 02516705
Why this matters
High risk of treatment failure
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
- 2
Check the model number
Model numbers are typically on the product label or packaging.
Affected models: DIN 02516691, DIN 02516705
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
High risk of treatment failure
What should consumers do?
Stop using the product if the Omicron variant cannot be ruled out. Consult with a healthcare professional for alternative treatments. Report any side effects to Hoffmann-La Roche Limited or Health Canada.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. High risk of treatment failure
When was this product recalled?
This product was recalled on January 7, 2022.
Is the Casirivimab and Imdevimab brand affected by this recall?
Yes, Casirivimab and Imdevimab products are affected by this recall. This recall involves Casirivimab and Imdevimab concentrate for infusion sold in Canada. It's being recalled because it may have a high risk of treatment failure against the SARS-CoV-2 Omicron variant. Healthcare professionals should consider other therapies if the Omicron variant cannot be ruled out.